Article
Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Journal of Alzheimer's disease : JAD - 1 Jan 2017
Villarreal Stephanie, Zhao Fuqiang, Hyde Lynn A, Holder Daniel, Forest Thomas, Sondey Marie, Chen Xia, Sur Cyrille, Parker Eric M, Kennedy Matthew E
Abstract excerpt
Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to-moderate and prodromal Alzheimer's disease. Multiple anti-amyloid immunotherapies have been dose-limited by adverse amyloid related imaging abnormalities such as vasogenic edema (ARIA-E) and microhemorrhage (ARIA-H) observed in human trials and mice. Verubecestat was tested in a 12-week...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
